Biotech Company to Sell Highest Purity Omega 3 Health Supplement in the UK and EU after Entering into Distribution Agreement with First Vitality International, LTD

Share Article

Omax3™, a pharmaceutical grade Omega 3 fatty acid health supplement, to be distributed in the United Kingdom and European Union.

News Image
This agreement with First Vitality is an important step forward in our efforts to expand our market from the United States into the United Kingdom and the European Union.

Cenestra Health, a privately-held, New Haven, Conn. based biotech company has entered into a distribution agreement with First Vitality International, LTD, to distribute its high purity Omega 3 supplement, Omax3™ The Ultra-Pure Omega 3 Supplement™, in the United Kingdom and European Union. Omax3 is a pharmaceutical grade health supplement that is currently available over-the-counter, without prescription, in the United States.

Ann Coric, M.D. of Cenestra Health commented, “This agreement with First Vitality is an important step forward in our efforts to expand our market from the United States into the United Kingdom and the European Union.” First Vitality is the largest internet distributor of pharmaceutical grade Omega 3 fatty acids in the UK and one of the definitive information resources for complementary nutritional medicine on the Internet. Omax3 is the highest purity Omega 3 health supplement available on the market providing an optimal ratio of EPA and DHA, the two most clinically important types of Omega 3s. Cenestra Health’s Omax3 has been dubbed The Ultra-Pure Omega 3 Supplement™ given its unsurpassed purity and medically formulated balance of EPA and DHA. Prior to this agreement with First Vitality, Cenestra Health has focused its distribution efforts on doctors, with direct educational health pieces to the public.

Omega 3 fatty acids have been shown in research to have numerous health benefits including decreasing the risk of arrhythmias, lowering triglyceride levels, slowing atherosclerotic plaque growth, decreasing blood pressure, enhancing mood, improving cognition, and supporting joint and skin health. Omax3 is preferred by healthcare providers due to its exceptionally high purity and minimal fish aftertaste. Dr. Coric, a practicing internist, added, “Taking a health supplement has to be effective and convenient for the consumer. Omax3 is taken once daily and is a comprehensive, full-spectrum supplement, intended to maximize beneficial effects across a wide range of physiologic systems.” Omax3™ delivers 1.5 grams of essential fatty acids per serving. Each softgel is over 91% pure Omega-3s and third party tested to ensure unsurpassed freshness, quality and purity.

For additional information on the news that is the subject of this release, contact Ann Coric M.D. or visit http://www.Omax3.com. Omax3™ and The Ultra-Pure Omega 3 Supplement™ are trademarks of Cenestra Health.

About Cenestra, LLC: Cenestra, LLC (D/B/A Cenestra Health) is a New Haven, Conn. based company founded to formulate and provide “best-in-class” natural products, which are based on sound research, manufactured to pharmaceutical grade quality and can be confidently recommended by physicians and healthcare professionals to their patients. Cenestra Health consultants include physicians and scientists from Yale University School of Medicine.

Contact:

Ann Coric, M.D.

Cenestra Health

877-879-6629

http://www.Omax3.com

About First Vitality International, LTD: First Vitality is the largest internet supplier of pharmaceutical grade Omega 3 supplements in the UK and is located in Guernsey, Channel Islands, United Kingdom. First Vitality’s trade division supplies specialist Omega supplement solutions to Independent Health stores, Pharmacies, and CAM practitioners. First Vitality is one of the most comprehensive information resources on the Internet for complementary nutritional medicine, with hundreds of pages of health data and research available at http://www.1stvitality.com.

Contact:

Dave Ferguson

First Vitality International, LTD

+0044 1928 797 044

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ann Coric
Visit website